Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NovoNordisk-FDA-File

More Like This

PR Newswire associated0

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

PR Newswire associated0

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

Camurus reports positive topline results for CAM2056, semaglutide monthly depot

PR Newswire associated0

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

First GLP-1 tablet for weight loss approved in the UK

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions